Bayer receives positive CHMP opinion for rivaroxaban for patients with coronary or peripheral artery disease (for specialized target groups only)

Positive CHMP opinion based on data from the largest Phase III rivaroxaban study, COMPASS / Once approved, rivaroxaban will be the only non-vitamin K antagonist oral anticoagulant (NOAC) indicated in combination with acetylsalicylic acid (ASA) for the prevention of atherothrombotic events in adult patients with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD) at high risk for ischaemic events
Source: Bayer Company News - Category: Pharmaceuticals Source Type: news